Novavax licenses virus-like particles

In a deal that could reach $5 million, Novavax

Randall C Willis
ROCKVILLE, Md.—In a deal that could reach $5 million, Novavax announced it signed a non-exclusive worldwide license agreement with Wyeth for rights to the latter's virus-like particle (VLP) technology for vaccine development. The deal includes upfront payments, as well as annual license fees, milestone payments, and royalties on sales of products arising from the deal.
 
"We are delighted to have completed this license agreement with Wyeth and see this license as another important step in building a strong intellectual property position for our influenza vaccine programs," says Rahul Singhvi, Novavax president and CEO.
 
VLPs have gained much attention in recent years as various labs worldwide have suggested that the protein complexes are able to induce stronger immune responses than typical vaccine antigens because of their structural similarity to viruses. Unlike viruses, however, VLPs lack genetic material and are therefore non-infectious.

Randall C Willis

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

February 2023 Front Cover

Latest Issue  

• Volume 19 • Issue 2 • February 2023

February 2023

February 2023 Issue